Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar Therapeutics announced positive results from its mid-stage REZOLVE-AD study for rezpegaldesleukin, which is an eczema treatment.

The Phase 2b REZOLVE-AD study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis (eczema), who had not previously received biologic or JAK inhibitor therapies. Patients received 3 under-the-skin injections of the drug. After 16 weeks, patients showed improvements in symptoms as measured by the Eczema Area and Severity Index/EASI.

Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin

A scientist in lab coat testing a new biopharmaceutical drug on a microscope.

Unlike many existing biologic treatments that block inflammatory cytokines, rezpegaldesleukin works by boosting the body’s natural anti-inflammatory mechanisms. The safety profile of rezpegaldesleukin was generally favorable, with mild to moderate injection site reactions being the most common adverse event, occurring in 69.7% of treated patients. These reactions were mostly mild to moderate, self-resolved, and did not lead to discontinuation. Nektar Therapeutics plans to present these 16-week induction data at a scientific meeting later in 2025.

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops therapies that selectively modulate the immune system to treat autoimmune disorders internationally.

While we acknowledge the potential of NKTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.